JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS Vol. 33, no. 3, 669-673 (2019)


Impact of mast cells in systemic lupus erythematosus: can inflammation be inhibited?

Caraffa A1, Gallenga CE2, Kritas SK3, Ronconi G4, Pio Conti 5.

Author information

1 School of Pharmacy, University of Camerino, Camerino, Italy.
2 Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.
3 Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.
4 Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.
5 Postgraduate Medical School, University of Chieti, Chieti, Italy.

Abstract

Systemic lupus erythematosus (SLE), is a complex chronic inflammatory autoimmune disease, with rheumatological manifestations, which afflicts mainly women. SLE presents various heterogeneous clinical aspects and different pathogeneses and involves the production of anti- DNA autoantibodies which are deposited as immune complexes in various organs and tissues, provoking inflammation. These diseases cause multiple tissue and organ damage in arthritis, skin lesions, hematologic changes, renal and neurologic disorders, and others (Table I). In SLE, serum contains anti-nucleus antibodies and anti-DNA antibodies that can be important biomarkers for patients suffering from this disease.

KEYWORDS:

cytokines, inflammation, IL-37, mast cell, systemic lupus erythematosus

Publication type

  • Editorial

You may also like...